-Phase 3 Results for HAT-301 Retrospective Trial Expected in Second Half 2023- Fourth Quarter 2022 Highlights Initiated Phase 3 Clinical Program to Advance PAX-101 Towards FDA Submission Appointed Stefan Schwabe MD, PhD as Chief Medical Officer Appointed Specialty Pharma Industry Leader Charles J. Casamento to Board of Directors Entered Into… Read More..

MILTON, NY, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it has received a new order exceeding $0.6 million from a customer in the clean energy sector, the first part of an expected multi-phase… Read More..

PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies. Greater selectivity of PMN310 for toxic oligomers indicates a potentially differentiated profile and supports further development TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a… Read More..